Elicio Therapeutics

OverviewSuggest Edit

Elicio Therapeutics is an immuno-oncology company, engineering therapies for cancer-killing immune responses. The Company is engineering potent cancer vaccines and immunotherapies for an array of aggressive solid and hematologic cancers. Elicio operates Amphiphile, a platform which enables precise targeting and delivery of immunogens directly to the lymphatic system, substantially enhancing the body’s own system of immune defenses, with the aim to achieve durable cures.

TypePrivate
Founded2018
HQCambridge, US
Websiteelicio.com

Latest Updates

Employees (est.) (Mar 2020)15(+8%)

Elicio Therapeutics Office Locations

Elicio Therapeutics has an office in Cambridge
Cambridge, US (HQ)
One Kendall Square Building 300 Suite 201
Show all (1)

Elicio Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2018

Elicio Therapeutics total Funding

$63 m

Elicio Therapeutics latest funding size

$33 m

Time since last funding

6 months ago

Elicio Therapeutics investors

Elicio Therapeutics's latest funding round in October 2019 was reported to be $33 m. In total, Elicio Therapeutics has raised $63 m
Show all financial metrics

Elicio Therapeutics Online and Social Media Presence

Embed Graph

Elicio Therapeutics Blogs

Elicio Therapeutics to discuss novel lymph node vaccine targeting seven key mKRAS mutations at RAS – Targeted Drug Discovery Summit in Vienna, Austria

Elicio Therapeutics, a next generation immuno-oncology company, today announced Peter DeMuth, PhD., Elicio Vice President of Research, will present “Targeting the Lymph Nodes to Enhance Mutant KRAS-Specific Vaccine Responses,” at the upcoming RAS-Targeted Drug Discovery Summit in Vienna, Austria, fr…

Elicio Therapeutics and Natera To Collaborate in Phase I/II Pancreatic Cancer Study of ELI-002

Elicio Therapeutics and Natera, Inc.(NASDAQ: NTRA) today announced their collaboration in a prospective, multicenter Phase 1/2 study of ELI-002, an Amphiphile immuno-oncology therapeutic targeting KRAS mutations in the adjuvant setting for patients with pancreatic ductal adenocarcinoma (PDAC) who ha…

ENDPOINTS: Christopher Haqq joins Elicio to hunt father’s RAS cancer

Christopher Haqq is now joining Elicio as its new R&D chief, overseeing the development of, among other things, their RAS-targeting immunotherapy. RAS mutations, which are now after 40 years of research becoming a prime target for experimental therapies, are present in about 30% of cancers, incl…

FIERCE BIOTECH: Chutes and Ladders

Cambridge, Massachusetts-based Elicio Therapeutics has hired Christopher Haqq, M.D., Ph.D., as CMO and executive vice president and head of R&D. Haqq was the first employee and CMO of Atara Biotherapeutics, and later its CSO. The post FIERCE BIOTECH: Chutes and Ladders appeared first on Elicio.

Physician-Scientist Christopher Haqq M.D., Ph.D. Joins Elicio Therapeutics as Research and Development Head

Will lead Elicio’s transition to clinical-stage and oversee, prioritize and advance the company’s rich pipeline of immunotherapies. The post Physician-Scientist Christopher Haqq M.D., Ph.D. Joins Elicio Therapeutics as Research and Development Head appeared first on Elicio.

ENDPOINTS: Elicio Therapeutics — focused on amphiphile immunotherapies — has closed its Series B with $33 million

Darrell Irvine co-founded Elicio Therapeutics — focused on amphiphile immunotherapies — has closed its Series B with $33 million. The company says that the financing will advance Elicio’s pipeline, including its amphiphile mKRAS vaccine, ELI-002 — which targets seven KRAS mutations that drive 99% of…
Show more

Elicio Therapeutics Frequently Asked Questions

  • When was Elicio Therapeutics founded?

    Elicio Therapeutics was founded in 2018.

  • How many employees does Elicio Therapeutics have?

    Elicio Therapeutics has 15 employees.

  • Who are Elicio Therapeutics competitors?

    Competitors of Elicio Therapeutics include DNAtriX, Inhibitor Therapeutics and Actuate Therapeutics.

  • Where is Elicio Therapeutics headquarters?

    Elicio Therapeutics headquarters is located at One Kendall Square Building 300 Suite 201, Cambridge.

  • Where are Elicio Therapeutics offices?

    Elicio Therapeutics has an office in Cambridge.

  • How many offices does Elicio Therapeutics have?

    Elicio Therapeutics has 1 office.